Search

Your search keyword '"Truyen, Luc"' showing total 34 results
Start Over Author "Truyen, Luc"
34 results on '"Truyen, Luc"'

1. Tackling gaps in developing life-changing treatments for dementia

Author

Mauricio, Rui, Benn, Caroline, Davis, John, Dawson, Gerry, Dawson, Lee A., Evans, Alison, Fox, Nick, Gallacher, John, Hutton, Mike, Isaac, John, Jones, Declan N.C., Jones, Lesley, Lalli, Giovanna, Libri, Vincenzo, Lovestone, Simon, Moody, Catherine, Noble, Wendy, Perry, Hugh, Pickett, James, Reynolds, David, Ritchie, Craig, Rohrer, Jonathan D., Routledge, Carol, Rowe, James, Snyder, Heather, Spires-Jones, Tara, Swartz, Jina, Truyen, Luc, and Whiting, Paul

Published
2019
Full Text
View/download PDF

8. The Authors Reply

Author

Wilcock, Gordon, Howe, Ian, Coles, Hilary, Lilienfeld, Sean, Truyen, Luc, Zhu, Young, and Bullock, Roger

Published
2003

15. [P3-077]: AN ADAPTED STAGED CONSENT MODEL FOR RECRUITMENT AND INFORMED CONSENT IN READINESS COHORTS: THE PERSPECTIVE OF THE EUROPEAN PREVENTION OF ALZHEIMER's DEMENTIA CONSORTIUM (EPAD)

Author

Tromp, Krista, primary, Bunnik, Eline, additional, Milne, Richard, additional, Badger, Shirlene, additional, Gove, Dianne, additional, Maman, Marianne, additional, Truyen, Luc, additional, Richard, Edo, additional, Schermer, Maartje, additional, and Smedinga, Marthe, additional

Published
2017
Full Text
View/download PDF

18. Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform

Author

Vaudano, Elisabetta, primary, Vannieuwenhuyse, Bart, additional, Geyten, Serge, additional, Lei, Johan, additional, Visser, Pieter Jelle, additional, Streffer, Johannes, additional, Ritchie, Craig, additional, McHale, Duncan, additional, Lovestone, Simon, additional, Hofmann‐Apitius, Martin, additional, Truyen, Luc, additional, and Goldman, Michel, additional

Published
2015
Full Text
View/download PDF

29. [sub 1]-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis: Relation to Inflammatory Activity.

Author

van Walderveen, Marianne A. A., Truyen, Luc, van Oosten, Bob W., Castelijns, Jonas A., Lycklama à Nijeholt, Geert J., van Waesberghe, Jan Hein T. M., Polman, Chris, and Barkhof, Frederik

Subjects
MULTIPLE sclerosis, GADOLINIUM, MAGNETIC resonance imaging
Abstract

Objective: To evaluate whether degree of inflammatory activity in multiple sclerosis, expressed by frequency of gadolinium enhancement, has prognostic value for development of hypointense lesions on T[sub 1]-weighted spin-echo magnetic resonance images, a putative marker of tissue destruction. Design: Cohort design with long-term follow-up. Thirty-eight patients with multiple sclerosis who in the past had been monitored with monthly gadolinium-enhanced magnetic resonance imaging for a median period of 10 months (range, 6-12 months) were reexamined after a median period of 40.5 months (range, 33-80 months). Setting: Magnetic Resonance Center for Multiple Sclerosis Research, Amsterdam, the Netherlands, referral center. Main Outcome Measures: The new enhancing lesion rate (median number of gadolinium-enhancing lesions per monthly scan) during initial monthly follow-up; hypointense T[sub 1] and hyperintense T[sub 2] lesion load at first and last visit. Results: The number of enhancing lesions on entry scan correlated with the new enhancing lesions rate (r=0.64; P<.001, Spearman rank correlation coefficient). The new enhancing lesion rate correlated with yearly increase in T[sub 1] (r=0.42; P<.01, Spearman rank correlation coefficient) and T[sub 2] (r=0.47; P<.01, Spearman rank correlation coefficient) lesion load. Initial T[sub 1] lesion load correlated more strongly with yearly increase in T[sub 1] lesion load (r=0.68; P<.01, Spearman rank correlation coefficient). Conclusions: Degree of inflammatory activity only partially predicted increase in T[sub 1] (and T[sub 2]) lesion load at long-term follow-up. Initial T[sub 1] lesion load strongly contributed to subsequent increase in hypointense T[sub 1] lesion load, suggesting that there is a subpopulation of patients with multiple sclerosis who are prone to develop destructive lesions. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

30. Multiple Sclerosis Therapy

Author

Oosten, Bob, Truyen, Luc, Barkhof, Frederik, and Polman, Chris

Abstract

A growing amount of evidence suggests that a disturbance of immunological function is of importance in the pathogenesis of multiple sclerosis. This is reflected in the drugs used to slow progression and to treat relapses. Immunosuppressive drugs such as azathioprine, cyclophosphamide and cyclosporin might have some potential to slow down progression of multiple sclerosis, but their use is limited by potentially serious adverse effects. Recently, it was shown that interferon-β-1b can diminish the exacerbation rate in multiple sclerosis without leading to unacceptable adverse effects. Nevertheless, symptomatic treatment remains of crucial importance in the management of multiple sclerosis patients. Spasticity, depression, fatigue and urinary, paroxysmal and sensory symptoms can all be alleviated to some extent with pharmacological interventions, although rehabilitation procedures and psychosocial consultations are no less important. Further therapeutic approaches to multiple sclerosis will be directed at either the specificity of the immune response or the grade of activation of the immune response. Magnetic resonance imaging techniques will play an important role in the evaluation of efficacy of new therapeutic agents.

Published
1995
Full Text
View/download PDF

31. Tackling gaps in developing life-changing treatments for dementia

Author

Mauricio, Rui, Benn, Caroline, Davis, John, Dawson, Gerry, Dawson, Lee A, Evans, Alison, Fox, Nick, Gallacher, John, Hutton, Mike, Isaac, John, Jones, Declan NC, Jones, Lesley, Lalli, Giovanna, Libri, Vincenzo, Lovestone, Simon, Moody, Catherine, Noble, Wendy, Perry, Hugh, Pickett, James, Reynolds, David, Ritchie, Craig, Rohrer, Jonathan D, Routledge, Carol, Rowe, James, Snyder, Heather, Spires-Jones, Tara, Swartz, Jina, Truyen, Luc, Whiting, Paul, and Therapeutics For Dementia Consortium

Subjects
Clinical trials, Diagnosis, Dementia, Disease-modifying treatment, Earlier detection, Genetic risk factors, Alzheimer's disease, Neurodegeneration, 3. Good health, Target validation
Abstract

Since the G8 dementia summit in 2013, a number of initiatives have been established with the aim of facilitating the discovery of a disease-modifying treatment for dementia by 2025. This report is a summary of the findings and recommendations of a meeting titled "Tackling gaps in developing life-changing treatments for dementia", hosted by Alzheimer's Research UK in May 2018. The aim of the meeting was to identify, review, and highlight the areas in dementia research that are not currently being addressed by existing initiatives. It reflects the views of leading experts in the field of neurodegeneration research challenged with developing a strategic action plan to address these gaps and make recommendations on how to achieve the G8 dementia summit goals. The plan calls for significant advances in (1) translating newly identified genetic risk factors into a better understanding of the impacted biological processes; (2) enhanced understanding of selective neuronal resilience to inform novel drug targets; (3) facilitating robust and reproducible drug-target validation; (4) appropriate and evidence-based selection of appropriate subjects for proof-of-concept clinical trials; (5) improving approaches to assess drug-target engagement in humans; and (6) innovative approaches in conducting clinical trials if we are able to detect disease 10-15 years earlier than we currently do today.

Catalog

Books, media, physical & digital resources
See catalog results